How is cancertrack™ validated?
CancertrackTM has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and speciﬁcity. Cancertrack™ has a combined sensitivity of 99.28% and a positive predictive value of 100%.
Why is early detection of molecular dynamics of cancer critical?
The molecular evolution of the tumour including tumour size and molecular diversity, is a continuous process, which is progressing at enormous speed. There are many strategies and drugs available today that can intercept cancerous growth effectively. Thus, earlier detection of the primary / recurrence / drug resistance is essential for an oncologist to make informed decisions.
How frequently is it necessary to do the test?
cancertrackTM should ideally be performed at every important milestone during cancer disease and especially when the tumour has disappeared from conventional imaging and the patient is under follow-up for recurrence monitoring.
What are the limitations of cancertrack™?
While cancertrackTM is extremely robust and multidimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.